Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 06, 2020
Revlon (REV, $7.23) posts wider-than-expected Q2 loss

Revlon (REV, $7.23) posts wider-than-expected Q2 loss

Revlon experienced a wider-than-expected  loss in the second quarter, amid covid-19 crisis.

The beauty/cosmetics company’s  adjusted loss of -$1.56 per share versus the Zacks Consensus Estimate of a loss of -$1.04. In the year-ago quarter, the loss was -$0.99 per share.

Revenue plunged -39% year-over-year to $347.6 million. Covid-19 led to an estimated negative impact of $214 million. Excluding the Covid-19 impact, net sales on a constant-currency basis were almost flat year-over-year.

However, e-commerce sales (accounting for 18% of total revenue in the quarter)climbed +58% from the year-ago quarter. Online sales accounted for 7% in the year-ago period.

REV enters an Uptrend because Momentum Indicator exceeded the 0 level on August 05, 2020

This indicator signals that REV's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the ticker or exploring call options. In 70 of 92 cases where REV's Momentum Indicator exceeded 0, its price rose further within the subsequent month. The odds of a continued Uptrend are 76%.

Current price $7.18 is below $9.10 the lowest support line found by A.I. Throughout the month of 07/06/20 - 08/05/20, the price experienced a -22% Downtrend, while the week of 07/29/20 - 08/05/20 shows a +20% Uptrend.

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a Downtrend to an Uptrend -- in cases where REV's RSI indicator exited the oversold zone, 23 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued Uptrend are 64%.

The Stochastic Indicator suggests the ticker price trend may be in a reversal from a Downtrend to an Uptrend. 45 of 62 cases where REV's Stochastic Indicator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued Uptrend are 73%.

The Moving Average Convergence Divergence (MACD) just turned positive. Considering data from situations where REV's MACD histogram became positive, in 29 of 40 cases, the price rose further within the following month. The odds of a continued Uptrend are 73%.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where REV advanced for three days, in 180 of 267 cases, the price rose further within the following month. The odds of a continued Uptrend are 67%.

The lower Bollinger Band was broken -- a price increase is expected as the ticker heads toward the middle band, which indicates a buy or call consideration for traders. In 28 of 42 cases where REV's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued Uptrend are 67%.

Bearish Trend Analysis

The Aroon Indicator entered a Downtrend today. In 158 of 192 cases where REV Aroon's Indicator entered a Downtrend, the price fell further within the following month. The odds of a continued Downtrend are 82%.

Fundamental Analysis (Ratings)

Tickeron has a negative outlook on this ticker and predicts a further decline by more than 4.00% within the next month with a likelihood of 73%. During the last month, the daily ratio of advancing to declining volumes was 1 to 1.86.

The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.30) is normal, around the industry mean (26.26). P/E Ratio (0.00) is within average values for comparable stocks, (47.64). Projected Growth (PEG Ratio) (1.05) is also within normal values, averaging (1.12). REV has a moderately low Dividend Yield (0.00) as compared to the industry average of (2.03). REV's P/S Ratio (0.25) is slightly lower than the industry average of (2.15).

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. REV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 65, placing this stock worse than average.

Related Ticker: REVRQ

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of and distributes hair and skincare products

Industry HouseholdPersonalCare

Profile
Details
Industry
Household Or Personal Care
Address
55 Water Street
Phone
+1 212 527-4000
Employees
5600
Web
https://www.revloninc.com
Interact to see
Advertisement
HIMS shares surged approximately +43.85% in premarket trading on Monday, March 9, 2026, rising from a prior close of $15.74 to around $22.80. Primary catalyst: Novo Nordisk officially ended its patent infringement lawsuit against Hims & Hers and announced a landmark partnership to distribute branded Wegovy through the Hims platform at $599/month.
XENE shares surged approximately +45.93% in premarket trading on March 9, 2026, one of the largest single-session moves in the company's history. The primary catalyst: Xenon announced positive topline Phase 3 X-TOLE2 results for its lead drug candidate azetukalner in focal onset seizures (FOS), meeting the primary endpoint with overwhelming statistical significance.
Shares of OLMA dropped approximately 41% in Monday's session, one of the steepest single-day declines in the company's history. The primary catalyst was Roche's Phase 3 persevERA trial failure — a late-stage study of giredestrant, a closely competing selective estrogen receptor degrader (SERD), which missed its primary endpoint of statistically significant improvement in progression-free survival.
RLMD shares surged approximately +40% at the open on March 9, 2026, rising from a prior close of $4.45 to approximately $6.23, driven by a major clinical trial readout. The primary catalyst was the announcement of 12-month interim data from the Phase 2 trial of NDV-01, Relmada's lead oncology candidate, in patients with high-risk non-muscle invasive bladder cancer (NMIBC) — results that significantly exceeded historical benchmarks.
CRCL surged +8.66% on Monday, March 9, 2026, rising from a prior close of $101.94 to trade at $110.77 intraday. The primary catalyst is a landmark stablecoin milestone: Circle's USDC overtook Tether as the dominant stablecoin by transfer volume, accounting for approximately 70% of all stablecoin transfer activity as total stablecoin transfers hit $1.8 trillion in February.
Carnival Corporation (CCL) shares fell approximately -7.60% in Monday's session, dropping from a Friday close of $25.79 to around $23.83. The primary catalyst is a broad market sell-off driven by intensifying recession fears, with the S&P 500 and consumer discretionary names bearing the brunt of the pressure.
Shares of Bloom Energy (BE) are surging approximately +10.30% in Monday's session, rebounding sharply from a steep -15.50% selloff on Friday, March 6, 2026. Friday's decline was triggered by an Oracle-OpenAI data center project update that spooked energy infrastructure investors; Monday's move reflects aggressive dip-buying and a sentiment reset.
IGV has rallied about 8–9% in the last 6 trading days, while SOXX has dropped about 8%, giving software a +16.6 percentage‑point edge—the largest 6‑day software‑over‑semi outperformance ever.[barchart]​ This comes right after software lagged semis by almost −15 percentage points into late January, the widest gap since 2008, and as hedge‑fund short exposure to U.S. software and services hit a record ~3.8% of market cap.
Crude’s explosive war‑driven spike faded on March 9 because the market suddenly started to price less extreme, shorter‑lived supply risk and more policy intervention, not a multi‑month shortage. WTI, which had briefly traded above 115–120 dollars on Iran‑war headlines and Strait of Hormuz fears, slid back toward the high‑80s as traders digested G7 reserve‑release talk, Trump’s comments about a “brief” war, and the reality that prices had run far ahead of fundamentals.
Shares of ARQ plunged approximately 27.50% in premarket trading on March 10, 2026, from a prior close of $3.20 to roughly $2.32. The primary catalyst was a deeply disappointing Q4 2025 earnings report, which revealed a net loss of $50.0 million for the quarter versus a net loss of $1.3 million in Q4 2024.
RAIL shares fell approximately 15% in premarket trading on March 10, 2026, following a steep after-hours reaction to disappointing Q4 2025 earnings results released after the close on March 9. The primary catalyst was a significant revenue miss: Q4 revenue came in at $125.6 million, well below consensus estimates near $144–$160 million, representing an 8.8% year-over-year decline.
ZVRA shares surged approximately +17.86% on March 10, 2026, driven by a blockbuster Q4 and full-year 2025 earnings report released before the market open. Primary catalyst: Q4 2025 EPS of $0.19 crushed the consensus estimate of $0.05 — a 280% beat — while revenue of $34.1 million exceeded forecasts by 21.57%.
LITE surged +14.73% on Monday, March 9, 2026, closing at $640.69 versus a prior close of $558.44 on March 6. The primary catalyst was the landmark $2 billion strategic investment by NVIDIA announced March 2, with the market continuing to price in its full implications following a brief post-announcement pullback.
Shares of BNTX fell approximately 22% on Tuesday, March 10, 2026, following a dual shock of disappointing full-year guidance and a surprise leadership upheaval. The primary catalyst was BioNTech's Q4 2025 earnings report, which included a 2026 revenue outlook of €2.0–€2.3 billion — well below analyst consensus and signaling continued pressure from declining COVID-19 vaccine demand.
CNC shares fell approximately 10% during Tuesday's session, extending a prolonged selloff in the managed care sector. The primary catalyst is intensifying investor concern over federal Medicaid and ACA funding cuts tied to the "One Big Beautiful Bill Act" (OBBBA), which threatens to shrink the government-sponsored insurance pools that Centene depends on for the majority of its revenue.
Technology recently peaked near 35% of the S&P 500 and has slipped over the last year, while Energy plus Materials remain near historically low combined weight at roughly 6%, which suggests the gap is still unusually wide.
Average daily equity purchases by retail investors on S&P 500 down days in 2026 are at the highest level on record, running about 100% above the peak intensity seen during the 2021 meme‑stock boom.
Over the past two weeks, PLTR has climbed from roughly the high‑130s to the mid‑150s, a gain of about 12–14%, with a series of strong up days between March 2 and March 6.
AVAV shares dropped approximately 10% in premarket trading on March 11, 2026, following a disappointing Q3 fiscal 2026 earnings report released after the prior session's close. Q3 revenue of $408.0 million came in far below analyst consensus of approximately $475–$488 million, representing a massive top-line miss.
KOS shares are down approximately 20% in premarket trading on March 11, 2026, having shed roughly 20.31% across the last two sessions (Tuesday close and premarket Wednesday). The primary catalyst is Kosmos Energy's announcement of a massive $185.25 million public equity offering priced at $1.90 per share — a steep discount to recent trading levels.